Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.59 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.59 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.59 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.59 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.59 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.59 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231529 | 0.99 | KDM4E (0.74) | KDM4EALDH1A1POLBMEN1CYP1A2 | |
| SCHEMBL10833328 | 0.81 | KDM4E (0.71) | KDM4EALDH1A1POLBMEN1CYP1A2 | |
| Bromide SCHEMBL6232392 | 0.80 | SIGMAR1 (0.58) | KDM4EALDH1A1POLBCYP1A2CYP3A4 | |
| Bromide SCHEMBL6232431 | 0.79 | HRH3 (0.62) | KDM4EALDH1A1MEN1CYP1A2CYP3A4 | |
| SCHEMBL6231596 | 0.79 | HRH3 (0.68) | KDM4EALDH1A1MEN1CYP1A2CYP3A4 | |
| SCHEMBL8879725 | 0.79 | MEN1 (0.75) | KDM4EALDH1A1POLBMEN1CYP1A2 | |
| SCHEMBL6232654 | 0.79 | SIGMAR1 (0.59) | KDM4EALDH1A1POLBCYP1A2CYP3A4 | |
| SCHEMBL16599328 | 0.78 | LMNA (0.64) | KDM4EALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL6229963 | 0.78 | HRH3 (0.63) | KDM4EALDH1A1MEN1CYP1A2CYP3A4 | |
| SCHEMBL108678 | 0.77 | KDM4E (0.70) | KDM4EMEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1025097-B1 | 1-(2-NAPHTHYL) AND 1-(2-AZANAPHTHYL)-4-(1-PHENYLMETHYL)PIPERAZINES BEING DOPAMINE D 4? RECEPTOR SUBTYPE LIGANDS | NEUROGEN CORP (US) | 2005-04-27 | — | — | EP | disclosed |
| CN-1191248-C | 1-(2-naphthyl) and 1(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine D4 receptor subtype ligands | NEUROGEN CORP (US) | 2005-03-02 | — | — | CN | disclosed |
| US-6384224-B2 | FOR THERAPY AND PROPHYLAXIS OF PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASE | NEUROGEN CORPORATION | 2002-05-07 | — | — | US | disclosed |
| US-20020013317-A1 | Certain 1- (2-naphthyl) and 1- (2- azanaphthyl) -4- (1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-6331629-B1 | TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-12-18 | — | — | US | disclosed |
| CN-1283195-A | 1-(2-naphthyl) and 1(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine D4 receptor subtype ligands | NEUROGEN CORP (US) | 2001-02-07 | — | — | CN | disclosed |
| US-6040448-A | USEFUL FOR TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES. | NEUROGEN CORPORATION (US) | 2000-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013317-A1 | Certain 1- (2-naphthyl) and 1- (2- azanaphthyl) -4- (1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands | DRD2, DRD4, DRD3 | HTR1A 16/4885ADRA2A 44/4885ADRA2B 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.